Search Results | Blood | American Society of Hematology

1-20 of 61

2 3 4

Sort by

Sort Order Select

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

DOI: https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

DOI: https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

Valentín García Gutiérrez, Luis Felipe Casado Montero, Raquel de Paz, María Teresa Gómez-Casares, Angel Ramírez Payer, Rosa Ayala, Raul Perez Lopez, Francisca Ferrer Marin, Blanca Xicoy, Juan Luis Steegmann, Fermin Sanchez-Guijo, Joaquín Martínez-López

Blood (2022) 140 (Supplement 1): 12206–12207.

DOI: https://doi.org/10.1182/blood-2022-165998

Published: 2022

Journal Articles

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)

Blood (2022) 140 (Supplement 1): 4570–4572.

DOI: https://doi.org/10.1182/blood-2022-166214

Published: 2022

Journal Articles

Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism

Antonio Perez, María Ovidia López, Rocío González-Sacristán, Mercedes Gasior, Antonio Marcos, Raquel De Paz Arias, José María Alonso, Carmen Mestre-Durán, Karima Al-Akioui, Cristina Ferreras, Antonio Balas, Jose Luis Vicario, Carlos Solano, Belén Estébanez, Esther Ramos-Boluda, Carlos Jiménez, Francisco Hernández-Oliveros

Blood (2022) 140 (Supplement 1): 10484–10485.

DOI: https://doi.org/10.1182/blood-2022-168909

Published: 2022

Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades

Blood (2021) 138 (Supplement 1): 242.

DOI: https://doi.org/10.1182/blood-2021-146154

Published: 2021

Journal Articles

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)

Blood (2021) 138 (Supplement 1): 1765.

DOI: https://doi.org/10.1182/blood-2021-150847

Published: 2021

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

DOI: https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Blood (2020) 136 (Supplement 1): 28–29.

DOI: https://doi.org/10.1182/blood-2020-140339

Published: 2020

Journal Articles

Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-139588

Published: 2020

Journal Articles

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood (2020) 135 (26): 2375–2387.

DOI: https://doi.org/10.1182/blood.2019003382

Published: 2020

Includes: Supplemental data

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

DOI: https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Blood (2018) 132 (Supplement 1): 468.

DOI: https://doi.org/10.1182/blood-2018-99-119430

Published: 2018

Journal Articles

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Blood (2018) 132 (Supplement 1): 3048.

DOI: https://doi.org/10.1182/blood-2018-99-111883

Published: 2018

Journal Articles

Procoagulant Mechanisms in Patients with Myelodysplastic Syndrome

Ihosvany Fernandez-Bello, Victor Jimenez-Yuste, Raquel de Paz, Mónica Martín, Raul Justo Sanz, Elena Monzón Manzano, Elena García Arias-Salgado, Maria Isabel Goyanes Martin, Teresa Álvarez-Roman, María Isabel Rivas Pollmar, Miguel A. Canales, Nora Butta

Blood (2017) 130 (Supplement 1): 4188.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4188.4188

Published: 2017

Journal Articles

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Valentín García-Gutierrez, MD, Felipe Casado, Fermín Sánchez-Guijo, MD PhD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, PhD, Joaquin Martinez-Lopez, Juan Luis Steegmann, MD

Blood (2016) 128 (22): 5450.

DOI: https://doi.org/10.1182/blood.V128.22.5450.5450

Published: 2016

Journal Articles

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Luis Felipe Casado Montero, Valentin Garcia Gutierrez, MD, Pilar Giraldo, MD PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, MD PhD, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann, MD PhD

Blood (2016) 128 (22): 3074.

DOI: https://doi.org/10.1182/blood.V128.22.3074.3074

Published: 2016

Journal Articles

Evaluation of Endothelial Damage in Sinusoidal Obstructive Syndrome

Nora Butta, PhD, Carmen de Ramón, MD, Raul Justo Sanz, BS Pharm, Elena Monzon Manzano, BSBC, Ihosvany Fernandez Bello, PhD, Mercedes Gasior, MD, Raquel De Paz, PhD, Karem Humala, MD, Pilar Gomez, MD, Ana Lopez de la Guia, MD, Marta Fabra, MD, Miguel Canales, MD PhD, Victor Jiménez Yuste, PhD

Blood (2016) 128 (22): 5802.

DOI: https://doi.org/10.1182/blood.V128.22.5802.5802

Published: 2016

Journal Articles

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

Blood (2016) 128 (22): 375.

DOI: https://doi.org/10.1182/blood.V128.22.375.375

Published: 2016

Journal Articles

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

María Díez Campelo, MD PhD, Julio Davila, MD, Sanchez Barba Mercedes, MD, Maria Lopez-Pavia, MD, Esperanza Such, PhD, Teresa Bernal, MD, Elisa Luño, Fernando Ramos, Marisa Calabuig, MD, Helena Pomares, MD, Bernardo Gonzalez, Brayan Merchan, MD, Edgardo Barranco, MD, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, MD, Ana I Vicente, PhD, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, MD, Jose Falantes, MD, Maria Jesus Arilla, Abelardo Bárez, MD, Regina Garcia, MD, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, MD, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, MD PhD, Luis Benlloch, Guillermo Sanz, MD PhD, María Consuelo Cañizo, MD PhD

Blood (2015) 126 (23): 2896.

DOI: https://doi.org/10.1182/blood.V126.23.2896.2896

Published: 2015

2 3 4

NARROW

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)

Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Procoagulant Mechanisms in Patients with Myelodysplastic Syndrome

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Evaluation of Endothelial Damage in Sinusoidal Obstructive Syndrome

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only